

ASX Release

**Oventus presents at the Digital Medicine & Medtech Showcase
in San Francisco**

Brisbane, Australia 10 January 2018: Oventus Medical Ltd (ASX: OVN), an Australian medical device company that is commercialising its suite of therapeutics for the treatment of sleep apnoea and snoring, is pleased to release the presentation that Founder and Clinical Director, Dr Chris Hart presented at the Digital Medicine & Medtech Showcase™, running in San Francisco between 8–10 January, the most important week in the annual meeting calendar for healthcare companies.

Presentation details

Date: Dr Hart presented on Tuesday 9 January
Time: The presentation was at 1:30 pm PST
Room: A-Cyril Magnin II (4th Floor)
Venue: PARC 55 Hotel, 55 Cyril Magnin St, San Francisco, CA 94102

Dr Hart, Founder and Clinical Director of Oventus, said, "We are delighted to be presenting at this highly respected conference. The United States is the world's largest market for sleep apnoea and snoring, and patients have largely been serviced to date using traditional CPAP therapies - which a high percentage of people find difficult to tolerate. We look forward to telling the story around how we are bringing patients back into care using our new approach, which in its short time on the market, has gained a strong patient following and notable body of clinical evidence."

Digital Medicine & Medtech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

Sara Demy-Colton, CEO of Demy-Colton, said: "We are delighted that Oventus will be presenting at the Digital Medicine & Medtech Showcase this year. Digital Medicine & Medtech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018."

For more information about the conference, please visit: <https://ebdgroup.knect365.com/digimed-showcase/agenda/1>.

For more information, please contact:

Mr Neil Anderson, Managing Director and CEO: M: +61 403 003 475

Jane Lowe, IR Department: M: +61 411 117 774 or jane.lowe@irdepartment.com.au

Additional links and information:

Follow Oventus on Twitter: @OventusLtd

Follow Digital Medicine & Medtech Showcase on Twitter: @EBDGroup and @Demy_Colton - #DIGIMEDSHOW

—ENDS—

About the Oventus O₂Vent Airway Technology

The Oventus O₂Vent is an oral appliance device which brings the lower jaw forward (a process commonly referred to as mandibular advancement) and incorporates an opening to the oral cavity to allow breathing through the device airway, minimising pressure swings during sleep.

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

About Oventus

Oventus is a Brisbane, Australia, based medical device company that has commercialized and brought to market a new **sleep treatment platform** for the treatment of sleep apnoea and snoring that enhances the treatment outcomes of both oral appliance therapy and CPAP therapy through increased efficacy and greater adherence.

Oral appliance: Oventus' unique and patented 'Airway Technology' incorporated into an oral appliance, the O₂Vent™, bypasses multiple levels of breathing obstruction including the nose, soft palate and tongue.

Our appliances are particularly designed for sufferers with nasal obstructions, soft palate collapse and who consequently tend to breathe through their mouth while sleeping.

In action, when nasal obstruction is present, breathing is supplemented through the O₂Vent™'s integrated 'Airways' delivering air to the back of the mouth while maintaining an oral seal, stabilizing the tongue base, bypassing obstructions in the nose and soft palate and reducing the collapsibility of the upper airway. However, when the nose is unobstructed, the O₂Vent™ allows for natural nasal breathing.

'O₂Vent™ Connect' Positive Airway Pressure (PAP) Connection: Severe sleep apnoea sufferers who have traditionally used a CPAP machine and full facemask can use Oventus' O₂Vent™ oral appliance

to interface with CPAP reducing operating pressure by around 66%, eliminating the need for straps and allowing physiologic mouth breathing while delivering CPAP. This has allowed for a re-design of the CPAP delivery system which is far less intrusive (without full face mask and straps), called the 'O₂Vent™ Connect'.

Oventus' O₂Vent™ Connect' attaches to the front of the O₂Vent™, thereby doing away with the full face mask, while bringing air from the CPAP machine to the nasal opening at lower pressure.

Clinical trials: Over 50 patients to date have shown Oventus' O₂Vent™ is successful in treating Obstructive Sleep Apnoea (OSA) by an additional 30-50% and that snoring was either eliminated or significantly reduced, when compared to mandibular or "jaw" advancement oral appliances which primarily reduce tongue based breathing obstruction. The positive results included those sufferers who had nasal obstructions and mainly breath through the mouth.

Market: According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP² due to discomfort caused from high operating pressure and low tolerance for a full face mask.

The Oventus oral appliance 'Airway Technology' in the O₂Vent™ when incorporated with Oventus' 'O₂Vent™ Connect' allows sufferers to breathe physiologically through the mouth or through the nose whilst simultaneously delivering CPAP. Mild sufferers are able to solely wear the O₂Vent™ oral appliance.

¹ Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003.*



Oventus: Innovators in Sleep Apnoea Treatment

Presentation for Medtech
& Digital Medicine
Showcase, San Francisco

January 2018 | #DIGIMEDSHOW

Twitter: @OventusLtd




About Oventus (ASX: OVN)

Oventus is commercializing its O₂Vent technology to treat Obstructive Sleep Apnoea

Our titanium, 3D printed airway technology “O₂Vent” enhances treatment outcomes **for more than half** of OSA patients



A close-up photograph of a man with dark hair and a beard, sleeping in a hospital bed. He is wearing a white medical device, possibly a CPAP mask or a similar respiratory aid, which is secured with straps around his head and under his chin. The device has a clear plastic window over the mouth area. He is lying on a light-colored pillow, and a blue blanket is visible over his shoulder. The background shows a white hospital sheet and a green wall.

Without the need
for one of these

A photograph of a bed with a light-colored wooden headboard. Three white pillows are arranged on the bed: two are propped up against the headboard, and one is in the foreground, slightly to the right. The bed is covered with a white sheet. The background is a plain, light-colored wall.

Obstructive sleep apnoea... more than just a poor night's sleep

**OSA impacts the way
people breathe when they
are sleeping.**

**Breathing is briefly
interrupted or becomes very
shallow during sleep.**

A light gray world map serves as a background. Five location pins are placed on the map: three in blue (North America, Europe, and East Asia) and two in orange (Australia and South America).

Poor sleep has major impacts on health economics

80%

Number of sleep apnoea sufferers understood to be out of care right now

\$26.2
BILLION

Financial losses in Australia between 2016-2017 from inadequate sleep

\$40.1
BILLION


Australia attributed \$40.1 billion to loss of well-being in 2016-2017

The big business of sleep

A photograph of a man and a woman in bed. The woman, on the left, is sleeping with her mouth wide open, illustrating obstructive sleep apnea. The man, on the right, is looking upwards with a concerned expression. They are lying on a bed with blue and white striped pillows.

Obstructive Sleep Apnoea (OSA) is a massive market.
It is worth US\$3.8** globally, growing at a CAGR of 15-20%.

** In 2015: Sleep Apnea Diagnostic & Therapeutic
Devices Market, Markets and Markets, Table 98.



Only 20% of OSA sufferers
are in care.

Why?

Their inability to tolerate
conventional treatment.



Does this look
comfortable to you?

How Oventus Airway technology works

The O₂Vent technology is the first major innovation in the treatment of sleep apnoea for years

1.

Air goes in through the airway on inhalation and out through the airway on exhalation.

Acts like a “second nose” when patient’s mouth is closed. An open mouth is undesirable when sleeping as an open jaw can cause breathing obstruction in the throat.



2.

Air in on inhalation delivered to throat, air out on exhalation

3.

The device brings the lower jaw forward, making more room for air to go into the patient’s lungs

Compelling clinical data

In clinical trials (and in real life) our devices succeeded where others could not.

Oventus Airway Technology:

- Makes mouth guards 30-50% more efficacious, and
- Dramatically reduces CPAP pressures and eliminates the need for masks, which
- Delivers significant competitive advantages for half of the current mouth guard and mask market of \$3.8billion/year, and

With the ability to bring more patients into care may well dramatically increase this addressable market

100%

Patients experienced significant improvement in snoring using O₂Vent

82%

Patients experienced complete elimination of snoring using O₂Vent

76%

Patients decreased their Apnoea-Hypopnea Index (AHI) using O₂Vent

With Oventus' oral device, many patients reported a good night's sleep...
*for the first time in **decades**.*



Distribution agreement with Modern Dental Group... the world's largest distributor of dental prosthetics

MODERN DENTAL GROUP LOCATIONS



Modern Dental is listed on HKSE

Ticker: 3600 | Market cap: \$2.21 b

Has 25% coverage of all dentists in USA
(34,000
dental offices through subsidiary,
Microdental)

Top 3 market share in all major European
countries

Australia's largest dental laboratory network

70+ sales and customer service centres
overseas

Focus on custom-made prostheses

Oventus' range is **the only premium device range** that Modern will sell



Exploring Licensing and partnering opportunities for the CPAP Interface applications

Oventus Airway Technology planned for launch into the US market 2H CY18


- It enables ultra low pressure CPAP delivery
- Without the need for a mask
- Making CPAP More tolerable
- With Access to existing reimbursement codes
- This is a significant competitive advantage in a \$3.5 Billion Dollar a year market^{*/**}

* Sleep Apnoea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98. China data – Anti-snoring Devices and Snoring Surgery Market: 2016-2024 p101

** Excludes cost of CPAP machine

Oventus Airway Technology – Coming soon.... O₂ Vent Connect PAP Connection

- Reduced PAP pressure requirements by 66%*
- Simultaneous CPAP delivery and physiologic mouth breathing
- Mask and mask-less (strap free) ultra low pressure PAP delivery



**Amatoury J, Tong B, Nguyen C, Szollosi I, Eckert DJ THE ROLE OF A NOVEL ORAL APPLIANCE THERAPY DEVICE ON PHARYNGEAL PRESSURE SWINGS AND CPAP REQUIREMENTS DURING SLEEP IN OBSTRUCTIVE SLEEP APNEA: A PILOT STUDY. Abstract Supplement ADSM Boston 2017*

Corporate snapshot

Oventus Medical Limited: ASX:OVN

Capital Structure

Shares on Issue	105.9m
Options	3.84m
Price (01/08/18)	\$0.62
Market Cap	\$65.7m

Cash on hand (30/6/17)	\$8,663,000
Revenue FY17	\$447,994





Investment summary (1/2)

1. Oventus (ASX: OVN) is driving the most significant change the sleep apnoea market has seen for years
2. Two key product ranges, both of which are set to disrupt a large and growing market:
 - O₂Vent Airway Technology oral appliance – currently generating revenue
 - CPAP machine* connector to O₂Vent– in late stage development (replaces face mask)
3. Clinical evidence validating the benefit of our proprietary airway is building

* CPAP machine: continuous positive airway pressure machine. Examples include by ResMed, Fisher & Paykel, and Phillips Respironics



Investment summary (2/2)

4. Agreement executed in June 2017 with world's largest dental prosthetics supplier, Modern Dental Group. Oventus and Modern now preparing for Modern to distribute Oventus' range globally through their established channels
 - Initial marketing preparations and training has been completed with the launch through Modern Dental Australia December 2017 and Modern Dental US scheduled for January 2017
 - Sales anticipated through Modern Dental from Q1 calendar 2018 and expected to accelerate in 2H calendar 2018
5. Obstructive Sleep Apnoea (OSA) is a massive market. US\$3.8** globally, growing at a CAGR of 15-20% with only 20% of OSA sufferers in care
6. Strong institutional investor interest and solid balance sheet

* CPAP machine: continuous positive airway pressure machine. Examples include by ResMed, Fisher & Paykel, and Phillips Respironics

** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98



"I HAVE USED THE OVENTUS DEVICE FOR 3 YEARS AND IT IS AMAZING.

No snoring and so easy to carry around. Used it right through Europe and did not have to worry about electricity or extra bags. Used a CPAP for 20 years. Now I am so free from all that. I love it!"

Jeanne Marshall

See more at www.oventus.com.au